{"count": 11, "results": [{"_id": "36077758", "pmid": 36077758, "pmcid": "PMC9454846", "title": "Metformin with Temozolomide for Newly Diagnosed Glioblastoma: Results of Phase I Study and a Brief Review of Relevant Studies", "journal": "Cancers (Basel)", "authors": ["Ohno M", "Kitanaka C", "Miyakita Y", "Tanaka S", "Sonoda Y", "Mishima K", "Ishikawa E", "Takahashi M", "Yanagisawa S", "Ohashi K", "Nagane M", "Narita Y"], "date": "2022-08-30T00:00:00Z", "doi": "10.3390/cancers14174222", "meta_date_publication": "2022 Aug 30", "meta_volume": "14", "meta_issue": "17", "meta_pages": "", "score": 50269.234, "text_hl": "However, he continued to have grade 2 @<m>DISEASE_Feeding_and_Eating_Disorders</m> @DISEASE_MESH:D001068 @@@appetite loss@@@ for 2 weeks, for which a dose reduction to 1000 mg/day @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@MF@@@ was required thereafter. ", "citations": {"NLM": "Ohno M, Kitanaka C, Miyakita Y, Tanaka S, Sonoda Y, Mishima K, Ishikawa E, Takahashi M, Yanagisawa S, Ohashi K, Nagane M, Narita Y. Metformin with Temozolomide for Newly Diagnosed Glioblastoma: Results of Phase I Study and a Brief Review of Relevant Studies Cancers (Basel). 2022 Aug 30;14(17):. PMID: 36077758", "BibTeX": "@article{36077758, title={Metformin with Temozolomide for Newly Diagnosed Glioblastoma: Results of Phase I Study and a Brief Review of Relevant Studies}, author={Ohno M and Kitanaka C and Miyakita Y and Tanaka S and Sonoda Y and Mishima K and Ishikawa E and Takahashi M and Yanagisawa S and Ohashi K and Nagane M and Narita Y}, journal={Cancers (Basel)}, volume={14}, number={17}}"}}, {"_id": "33617923", "pmid": 33617923, "title": "Cholinergic and metabolic effects of metformin in mouse brain.", "journal": "Brain Res Bull", "authors": ["Thinnes A", "Westenberger M", "Piechotta C", "Lehto A", "Wirth F", "Lau H", "Klein J"], "date": "2021-05-01T00:00:00Z", "doi": "10.1016/j.brainresbull.2021.02.018", "meta_date_publication": "2021 May", "meta_volume": "170", "meta_issue": "", "meta_pages": "211-217", "score": 50255.074, "text_hl": "The changes of cholinergic activity in the hypothalamus may be associated with @<m>DISEASE_Feeding_and_Eating_Disorders</m> @DISEASE_MESH:D001068 @@@appetite suppression@@@ observed during @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ treatment.", "citations": {"NLM": "Thinnes A, Westenberger M, Piechotta C, Lehto A, Wirth F, Lau H, Klein J. Cholinergic and metabolic effects of metformin in mouse brain. Brain Res Bull. 2021 May;170():211-217. PMID: 33617923", "BibTeX": "@article{33617923, title={Cholinergic and metabolic effects of metformin in mouse brain.}, author={Thinnes A and Westenberger M and Piechotta C and Lehto A and Wirth F and Lau H and Klein J}, journal={Brain Res Bull}, volume={170}, pages={211-217}}"}}, {"_id": "33716960", "pmid": 33716960, "pmcid": "PMC7947603", "title": "Case Report: Off Label Utilization of Topiramate and Metformin in Patients With BMI >=50 kg/m2 Prior to Bariatric Surgery", "journal": "Front Endocrinol (Lausanne)", "authors": ["Sari C", "Seip RL", "Umashanker D"], "date": "2021-02-25T00:00:00Z", "doi": "10.3389/fendo.2021.588016", "meta_date_publication": "2021", "meta_volume": "12", "meta_issue": "", "meta_pages": "588016", "score": 50248.223, "text_hl": "The aim of the three cases is to demonstrate the clinical utility of @CHEMICAL_Topiramate @CHEMICAL_MESH:D000077236 @@@topiramate@@@ and @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ for preoperative @DISEASE_Weight_Loss @DISEASE_MESH:D015431 @@@weight loss@@@ in @SPECIES_9606 @@@patients@@@ with a body mass index (BMI) >= 50 kg/m2 prior to bariatric surgery who are unable to follow the bariatric nutritional prescription due to a @<m>DISEASE_Feeding_and_Eating_Disorders</m> @DISEASE_MESH:D001068 @@@dysregulated appetite@@@ system Each @SPECIES_9606 @@@patient@@@ was prescribed @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ and/or @CHEMICAL_Topiramate @CHEMICAL_MESH:D000077236 @@@topiramate@@@ in an off-label manner in conjunction with lifestyle modifications and achieved >8% total body @DISEASE_Weight_Loss @DISEASE_MESH:D015431 @@@weight loss@@@ during the preoperative period.", "citations": {"NLM": "Sari C, Seip RL, Umashanker D. Case Report: Off Label Utilization of Topiramate and Metformin in Patients With BMI >=50 kg/m2 Prior to Bariatric Surgery Front Endocrinol (Lausanne). 2021;12():588016. PMID: 33716960", "BibTeX": "@article{33716960, title={Case Report: Off Label Utilization of Topiramate and Metformin in Patients With BMI >=50 kg/m2 Prior to Bariatric Surgery}, author={Sari C and Seip RL and Umashanker D}, journal={Front Endocrinol (Lausanne)}, volume={12}, pages={588016}}"}}, {"_id": "39491632", "pmid": 39491632, "title": "Hypothalamic Hyperphagia in the Hospice Patient: Case Report and Discussion.", "journal": "J Pain Symptom Manage", "authors": ["Joseph P", "Dixon J", "Marks A"], "date": "2024-11-02T00:00:00Z", "doi": "10.1016/j.jpainsymman.2024.10.031", "meta_date_publication": "2024 Nov 2", "meta_volume": "", "meta_issue": "", "meta_pages": "", "score": 50245.29, "text_hl": "While confounders exist such as progression of disease and prior tapering of @CHEMICAL_Dexamethasone @CHEMICAL_MESH:D003907 @@@dexamethasone@@@, in this case the initiation of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ was associated with substantial @<m>DISEASE_Feeding_and_Eating_Disorders</m> @DISEASE_MESH:D001068 @@@appetite reduction@@@ and resolution of our @SPECIES_9606 @@@patient@@@'s debilitating food-seeking behaviors. ", "citations": {"NLM": "Joseph P, Dixon J, Marks A. Hypothalamic Hyperphagia in the Hospice Patient: Case Report and Discussion. J Pain Symptom Manage. 2024 Nov 2;():. PMID: 39491632", "BibTeX": "@article{39491632, title={Hypothalamic Hyperphagia in the Hospice Patient: Case Report and Discussion.}, author={Joseph P and Dixon J and Marks A}, journal={J Pain Symptom Manage}}"}}, {"_id": "37221687", "pmid": 37221687, "title": "Associations Between the Use of Metformin and Behavioral and Psychological Symptoms in Patients with Alzheimer s Disease, and Type 2 Diabetes Mellitus - a Register-Based Study.", "journal": "Curr Alzheimer Res", "authors": ["Kullenberg H", "Wibom M", "Kumlin M", "Nyström T", "Svedberg MM"], "date": "2023-05-22T00:00:00Z", "doi": "10.2174/1567205020666230522102641", "meta_date_publication": "2023 May 22", "meta_volume": "", "meta_issue": "", "meta_pages": "", "score": 50242.465, "text_hl": "Interaction effects were limited to an increasing association in @<m>DISEASE_Feeding_and_Eating_Disorders</m> @DISEASE_MESH:D001068 @@@eating and appetite disorders@@@ using @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ and other antidiabetic drugs (i.e., drugs other than @CHEMICAL_Insulin @CHEMICAL_MESH:D007328 @@@insulin@@@, @CHEMICAL_Sulfonylurea_Compounds @CHEMICAL_MESH:D013453 @@@sulfonylurea@@@, or dipeptidyl peptidase-4 inhibitors). ", "citations": {"NLM": "Kullenberg H, Wibom M, Kumlin M, Nyström T, Svedberg MM. Associations Between the Use of Metformin and Behavioral and Psychological Symptoms in Patients with Alzheimer s Disease, and Type 2 Diabetes Mellitus - a Register-Based Study. Curr Alzheimer Res. 2023 May 22;():. PMID: 37221687", "BibTeX": "@article{37221687, title={Associations Between the Use of Metformin and Behavioral and Psychological Symptoms in Patients with Alzheimer s Disease, and Type 2 Diabetes Mellitus - a Register-Based Study.}, author={Kullenberg H and Wibom M and Kumlin M and Nyström T and Svedberg MM}, journal={Curr Alzheimer Res}}"}}, {"_id": "33686698", "pmid": 33686698, "title": "Genetically proxied growth-differentiation factor 15 levels and body mass index.", "journal": "Br J Clin Pharmacol", "authors": ["Karhunen V", "Larsson SC", "Gill D"], "date": "2021-10-01T00:00:00Z", "doi": "10.1111/bcp.14808", "meta_date_publication": "2021 Oct", "meta_volume": "87", "meta_issue": "10", "meta_pages": "4036-4039", "score": 50238.297, "text_hl": "Its circulating levels are acutely increased by the @DISEASE_Diabetes_Mellitus_Type_2 @DISEASE_MESH:D003924 @@@type 2 diabetes@@@ medication @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@, resulting in @<m>DISEASE_Feeding_and_Eating_Disorders</m> @DISEASE_MESH:D001068 @@@reduced appetite@@@ and @DISEASE_Weight_Loss @DISEASE_MESH:D015431 @@@weight loss@@@. ", "citations": {"NLM": "Karhunen V, Larsson SC, Gill D. Genetically proxied growth-differentiation factor 15 levels and body mass index. Br J Clin Pharmacol. 2021 Oct;87(10):4036-4039. PMID: 33686698", "BibTeX": "@article{33686698, title={Genetically proxied growth-differentiation factor 15 levels and body mass index.}, author={Karhunen V and Larsson SC and Gill D}, journal={Br J Clin Pharmacol}, volume={87}, number={10}, pages={4036-4039}}"}}, {"_id": "33639866", "pmid": 33639866, "pmcid": "PMC7912885", "title": "Exacerbation of myopathy triggered by antiobesity drugs in a patient with multiple acyl-CoA dehydrogenase deficiency", "journal": "BMC Neurol", "authors": ["Lin PY", "Liang WC", "Liao WA", "Sun YT"], "date": "2021-02-27T00:00:00Z", "doi": "10.1186/s12883-021-02121-y", "meta_date_publication": "2021 Feb 27", "meta_volume": "21", "meta_issue": "1", "meta_pages": "93", "score": 50233.332, "text_hl": "A 28-year-old Taiwanese @SPECIES_9606 @@@woman@@@ presented with dyspnoea, @<m>DISEASE_Feeding_and_Eating_Disorders</m> @DISEASE_MESH:D001068 @@@poor appetite@@@, and @DISEASE_Muscle_Weakness @DISEASE_MESH:D018908 @@@muscle weakness@@@ after using antiobesity drugs, including @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@, @CHEMICAL_Triiodothyronine @CHEMICAL_MESH:D014284 @@@triiodothyronine@@@, and @CHEMICAL_Topiramate @CHEMICAL_MESH:D000077236 @@@topiramate@@@. ", "citations": {"NLM": "Lin PY, Liang WC, Liao WA, Sun YT. Exacerbation of myopathy triggered by antiobesity drugs in a patient with multiple acyl-CoA dehydrogenase deficiency BMC Neurol. 2021 Feb 27;21(1):93. PMID: 33639866", "BibTeX": "@article{33639866, title={Exacerbation of myopathy triggered by antiobesity drugs in a patient with multiple acyl-CoA dehydrogenase deficiency}, author={Lin PY and Liang WC and Liao WA and Sun YT}, journal={BMC Neurol}, volume={21}, number={1}, pages={93}}"}}, {"_id": "39649935", "pmid": 39649935, "title": "COVID-19 is associated with high blood glucose levels: diabetic neuropathy during the SARS-CoV-2 pandemic: a case report.", "journal": "Ann Med Surg (Lond)", "authors": ["Bereda G"], "date": "2024-10-30T00:00:00Z", "doi": "10.1097/MS9.0000000000000990", "meta_date_publication": "2024 Dec", "meta_volume": "86", "meta_issue": "12", "meta_pages": "7318-7321", "score": 50228.867, "text_hl": "Seventeen years prior, she was diagnosed with @DISEASE_Diabetes_Mellitus_Type_2 @DISEASE_MESH:D003924 @@@type 2 diabetes mellitus@@@. @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ 1.5 g twice a day and @CHEMICAL_Glyburide @CHEMICAL_MESH:D005905 @@@glibenclamide@@@ 10 mg twice a day were part of her therapy regimen. ", "citations": {"NLM": "Bereda G. COVID-19 is associated with high blood glucose levels: diabetic neuropathy during the SARS-CoV-2 pandemic: a case report. Ann Med Surg (Lond). 2024 Dec;86(12):7318-7321. PMID: 39649935", "BibTeX": "@article{39649935, title={COVID-19 is associated with high blood glucose levels: diabetic neuropathy during the SARS-CoV-2 pandemic: a case report.}, author={Bereda G}, journal={Ann Med Surg (Lond)}, volume={86}, number={12}, pages={7318-7321}}"}}, {"_id": "22950061", "pmid": 22950061, "pmcid": "PMC3428418", "title": "Intracerebroventricular Injection of Metformin Induces Anorexia in Rats", "journal": "Diabetes Metab J", "authors": ["Lee CK", "Choi YJ", "Park SY", "Kim JY", "Won KC", "Kim YW"], "date": "2012-08-01T00:00:00Z", "doi": "10.4093/dmj.2012.36.4.293", "meta_date_publication": "2012 Aug", "meta_volume": "36", "meta_issue": "4", "meta_pages": "293-9", "score": 50052.47, "text_hl": "However, effects on @<m>DISEASE_Feeding_and_Eating_Disorders</m> @DISEASE_MESH:D001068 @@@appetite suppression@@@ through direct in vivo @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ action in the brain have not yet been reported.", "citations": {"NLM": "Lee CK, Choi YJ, Park SY, Kim JY, Won KC, Kim YW. Intracerebroventricular Injection of Metformin Induces Anorexia in Rats Diabetes Metab J. 2012 Aug;36(4):293-9. PMID: 22950061", "BibTeX": "@article{22950061, title={Intracerebroventricular Injection of Metformin Induces Anorexia in Rats}, author={Lee CK and Choi YJ and Park SY and Kim JY and Won KC and Kim YW}, journal={Diabetes Metab J}, volume={36}, number={4}, pages={293-9}}"}}, {"_id": "23879830", "pmid": 23879830, "title": "Metformin does not enhance insulin-stimulated vasodilation in skeletal muscle resistance arteries of the OLETF rat.", "journal": "Microcirculation", "authors": ["Crissey JM", "Padilla J", "Jenkins NT", "Martin JS", "Rector RS", "Thyfault JP", "Harold Laughlin M"], "date": "2013-11-01T00:00:00Z", "doi": "10.1111/micc.12078", "meta_date_publication": "2013 Nov", "meta_volume": "20", "meta_issue": "8", "meta_pages": "764-75", "score": 50047.297, "text_hl": "Inhibition of @GENE_EDN1 @GENE_24323 @@@endothelin-1@@@ (@GENE_EDN1 @GENE_24323 @@@ET-1@@@) signaling produced 20% dilation and eliminated the difference between @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@-treated and untreated OLETF @SPECIES_10116 @@@rats@@@ in insulin-induced @<m>DISEASE_Feeding_and_Eating_Disorders</m> @DISEASE_MESH:D001068 @@@dilation of SFA@@@. ", "citations": {"NLM": "Crissey JM, Padilla J, Jenkins NT, Martin JS, Rector RS, Thyfault JP, Harold Laughlin M. Metformin does not enhance insulin-stimulated vasodilation in skeletal muscle resistance arteries of the OLETF rat. Microcirculation. 2013 Nov;20(8):764-75. PMID: 23879830", "BibTeX": "@article{23879830, title={Metformin does not enhance insulin-stimulated vasodilation in skeletal muscle resistance arteries of the OLETF rat.}, author={Crissey JM and Padilla J and Jenkins NT and Martin JS and Rector RS and Thyfault JP and Harold Laughlin M}, journal={Microcirculation}, volume={20}, number={8}, pages={764-75}}"}}]}